Align Technology stock steadies after VAT hit while Q2 revenue grows modestly

Align Technology stock (ISIN US0162551016) closed at USD 147.61 on Nasdaq on September 18, 2026, representing a 1.40 percent decline versus the previous session and leaving the shares slightly below their level at the start of 2026, according to recent quote data from MarketBeat and Reuters cited in a market wrap dated September 19, 2026.

Q2 2026 revenue grows while mix shifts

In its most recent reported quarter, Align Technology delivered record second quarter 2026 revenue of USD 1.06 billion, an increase of 4.3 percent year on year, reflecting continued demand for its Invisalign clear aligners and related services, as reported by Dental Tribune on September 21, 2026.

Within that total, revenue from Align Technology's core aligner business rose 8.2 percent year on year in the second quarter of 2026 to USD 871 million, while sales from imaging systems and CAD/CAM services declined 10.8 percent to USD 185 million, highlighting a shift in the revenue mix toward its orthodontic aligner products, according to the same Dental Tribune report.

Operationally, Align Technology recorded record aligner shipments of 691,785 cases in the second quarter of 2026, up 7.4 percent compared with the same period a year earlier, and increased the number of Invisalign-trained dentists receiving cases to 89,175 from 86,250, while the average number of cases shipped per participating dentist rose from 7.5 to 7.8, illustrating both broader adoption and higher utilization per provider, as detailed by Dental Tribune.

VAT ruling in the U.K. adds a new cost headwind

A fresh regulatory development in the United Kingdom has added a new cost and pricing dimension for Align Technology. In July 2026, the U.K. Upper Tribunal overturned a previous VAT exemption ruling for clear aligners, prompting Align Technology to record an estimated liability of USD 37.5 million, including interest, and to start applying a 20 percent value-added tax to applicable Invisalign aligners and Vivera retainers sold in the U.K. from September 7, 2026, without changing list prices, according to a report from Zacks published on September 21, 2026.

The company intends to appeal the Upper Tribunal decision, and the ultimate financial impact remains uncertain, but the combination of the USD 37.5 million estimated liability and ongoing 20 percent VAT on U.K. Invisalign and Vivera sales introduces a tangible margin headwind in that market segment, as highlighted by the same Zacks commentary.

Stock valuation and recent trading context

Based on recent quote overviews, Align Technology stock's closing price of USD 147.61 on Nasdaq on September 18, 2026, with a 1.40 percent daily decline versus the prior session, leaves the shares modestly below their level at the beginning of 2026 and below the highs seen around the summer 2026 earnings release, per data cited by MarketBeat and Reuters in an article dated September 19, 2026.

For investors, the quantified combination of a 4.3 percent year-on-year increase in second quarter 2026 revenue to USD 1.06 billion, an 8.2 percent rise in aligner revenue to USD 871 million against a 10.8 percent drop in imaging and CAD/CAM revenue to USD 185 million, and the USD 37.5 million VAT-related liability recorded in July 2026 provides a clearer picture of how Align Technology is balancing growth in its core clear aligner business with pressures in ancillary segments and new regulatory costs, as described by Dental Tribune and Zacks.

Recent price level on Nasdaq

As of the last completed trading day referenced in available quote summaries, Align Technology stock traded at a closing level of USD 147.61 on Nasdaq on September 18, 2026, with that price representing a 1.40 percent decrease compared with the previous close and leaving the shares moderately below the recent highs reached around the publication of the second quarter 2026 results.

More news and analyses on Align Technology stock